Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
AstraZeneca PLC is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines, particularly in oncology, cardiovascular, renal, and respiratory diseases. With a strong pipeline of innovative therapies and a significant presence in markets such as the U.S. and Europe, AstraZeneca's competitive advantage lies in its robust R&D capabilities and strategic partnerships.
AstraZeneca generates revenue primarily through the sale of patented pharmaceuticals, leveraging strong pricing power due to its innovative drug portfolio. The company benefits from economies of scale in production and distribution, as well as strategic collaborations with other pharmaceutical companies and research institutions.
Regulatory approvals for new drugs, particularly in oncology and rare diseases
Sales performance of key products like Tagrisso and Farxiga
Pipeline developments and clinical trial results
Market share changes in key therapeutic areas
Regulatory changes impacting drug pricing and approvals
Technological disruption in drug development processes
Increased competition from generic drugs post-patent expiration
Emerging biotech companies with innovative therapies
Moderate debt levels may pose risks if cash flows decline
Potential pension obligations impacting liquidity
moderate - AstraZeneca's performance is somewhat linked to GDP growth, as healthcare spending tends to rise in stronger economic conditions.
Interest rates affect AstraZeneca primarily through the cost of capital for R&D investments. Higher rates may increase financing costs, impacting profitability and valuation multiples.
minimal - AstraZeneca's solid cash flow and manageable debt levels reduce reliance on credit markets.
growth - AstraZeneca's strong pipeline and innovative drug portfolio appeal to growth-oriented investors.
moderate - Historical volatility has been in line with industry averages, reflecting both growth potential and inherent risks.